WHAT MAKES US LEADERS
VARIETY OF FORMATS AND PRESENTATIONS
In the form of Ampoules, Liquid and Lyophilized Vials, Hypak® prefilled syringes, Uniject® Devices and Solids.
MR PHARMA has a Development Department that performs lyophilized recombinant high complexity formulations, control release and liposomal nano carriers. It has its own registry of Pegylated Liposomal Doxorubicin, applied nanotechnology that allows the discrimination of toxicity and increases the effectiveness of chemotherapeutic agents. It is also developing other nanocarriers formulations, studying the phases of stability and comparative toxicity testing.